Plasma matrix metalloproteinase 1 improves the detection and survival prediction of esophageal squamous cell carcinoma

Yu Kuei Chen, Chun Wei Tung, Jui Ying Lee, Yi Chun Hung, Chien Hung Lee, Shah Hwa Chou, Hung Shun Lin, Ming Tsang Wu, I. Chen Wu

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

This study aimed to identify noninvasive protein markers capable of detecting the presence and prognosis of esophageal squamous-cell carcinoma (ESCC). Analyzing microarray expression data collected from 17-pair ESCC specimens, we identified one protein, matrix metalloproteinase-1 (MMP1), as a possibly useful marker. Plasma MMP1 was then measured by enzyme-linked immunosorbent assay (ELISA) in 210 ESCC patients and 197 healthy controls. ESCC patients had higher mean levels of MMP1 than controls (8.7 ± 7.5 vs. 6.7 ± 4.9 ng/mL, p < 0.0001). Using the highest quartile level (9.67 ng/mL) as cut-off, we found a 9.0-fold risk of ESCC in those with higher plasma MMP1 after adjusting for covariates (95% confidence interval = 2.2, 36.0). Heavy smokers and heavy drinkers with higher plasma MMP1 had 61.4-and 31.0 times the risk, respectively, than non-users with lower MMP1. In the survival analysis, compared to those with MMP1 ≤ 9.67 ng/mL, ESCC patients with MMP1 > 9.67 ng/mL had a 48% increase in the risk of ESCC death (adjusted hazard ratio = 1.48; 95% CI = 1.04-2.10). In conclusion, plasma MMP1 may serve as a noninvasive marker of detecting the presence and predicting the survival of ESCC.

Original languageEnglish
Article number30057
JournalScientific Reports
Volume6
DOIs
Publication statusPublished - Jul 20 2016
Externally publishedYes

Fingerprint

Matrix Metalloproteinase 1
Survival
Esophageal Squamous Cell Carcinoma
Proteins
Cell Death
Enzyme-Linked Immunosorbent Assay

ASJC Scopus subject areas

  • General

Cite this

Plasma matrix metalloproteinase 1 improves the detection and survival prediction of esophageal squamous cell carcinoma. / Chen, Yu Kuei; Tung, Chun Wei; Lee, Jui Ying; Hung, Yi Chun; Lee, Chien Hung; Chou, Shah Hwa; Lin, Hung Shun; Wu, Ming Tsang; Wu, I. Chen.

In: Scientific Reports, Vol. 6, 30057, 20.07.2016.

Research output: Contribution to journalArticle

Chen, Yu Kuei ; Tung, Chun Wei ; Lee, Jui Ying ; Hung, Yi Chun ; Lee, Chien Hung ; Chou, Shah Hwa ; Lin, Hung Shun ; Wu, Ming Tsang ; Wu, I. Chen. / Plasma matrix metalloproteinase 1 improves the detection and survival prediction of esophageal squamous cell carcinoma. In: Scientific Reports. 2016 ; Vol. 6.
@article{b3a33812323a415ab4531720ad8d8e93,
title = "Plasma matrix metalloproteinase 1 improves the detection and survival prediction of esophageal squamous cell carcinoma",
abstract = "This study aimed to identify noninvasive protein markers capable of detecting the presence and prognosis of esophageal squamous-cell carcinoma (ESCC). Analyzing microarray expression data collected from 17-pair ESCC specimens, we identified one protein, matrix metalloproteinase-1 (MMP1), as a possibly useful marker. Plasma MMP1 was then measured by enzyme-linked immunosorbent assay (ELISA) in 210 ESCC patients and 197 healthy controls. ESCC patients had higher mean levels of MMP1 than controls (8.7 ± 7.5 vs. 6.7 ± 4.9 ng/mL, p < 0.0001). Using the highest quartile level (9.67 ng/mL) as cut-off, we found a 9.0-fold risk of ESCC in those with higher plasma MMP1 after adjusting for covariates (95{\%} confidence interval = 2.2, 36.0). Heavy smokers and heavy drinkers with higher plasma MMP1 had 61.4-and 31.0 times the risk, respectively, than non-users with lower MMP1. In the survival analysis, compared to those with MMP1 ≤ 9.67 ng/mL, ESCC patients with MMP1 > 9.67 ng/mL had a 48{\%} increase in the risk of ESCC death (adjusted hazard ratio = 1.48; 95{\%} CI = 1.04-2.10). In conclusion, plasma MMP1 may serve as a noninvasive marker of detecting the presence and predicting the survival of ESCC.",
author = "Chen, {Yu Kuei} and Tung, {Chun Wei} and Lee, {Jui Ying} and Hung, {Yi Chun} and Lee, {Chien Hung} and Chou, {Shah Hwa} and Lin, {Hung Shun} and Wu, {Ming Tsang} and Wu, {I. Chen}",
year = "2016",
month = "7",
day = "20",
doi = "10.1038/srep30057",
language = "English",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Plasma matrix metalloproteinase 1 improves the detection and survival prediction of esophageal squamous cell carcinoma

AU - Chen, Yu Kuei

AU - Tung, Chun Wei

AU - Lee, Jui Ying

AU - Hung, Yi Chun

AU - Lee, Chien Hung

AU - Chou, Shah Hwa

AU - Lin, Hung Shun

AU - Wu, Ming Tsang

AU - Wu, I. Chen

PY - 2016/7/20

Y1 - 2016/7/20

N2 - This study aimed to identify noninvasive protein markers capable of detecting the presence and prognosis of esophageal squamous-cell carcinoma (ESCC). Analyzing microarray expression data collected from 17-pair ESCC specimens, we identified one protein, matrix metalloproteinase-1 (MMP1), as a possibly useful marker. Plasma MMP1 was then measured by enzyme-linked immunosorbent assay (ELISA) in 210 ESCC patients and 197 healthy controls. ESCC patients had higher mean levels of MMP1 than controls (8.7 ± 7.5 vs. 6.7 ± 4.9 ng/mL, p < 0.0001). Using the highest quartile level (9.67 ng/mL) as cut-off, we found a 9.0-fold risk of ESCC in those with higher plasma MMP1 after adjusting for covariates (95% confidence interval = 2.2, 36.0). Heavy smokers and heavy drinkers with higher plasma MMP1 had 61.4-and 31.0 times the risk, respectively, than non-users with lower MMP1. In the survival analysis, compared to those with MMP1 ≤ 9.67 ng/mL, ESCC patients with MMP1 > 9.67 ng/mL had a 48% increase in the risk of ESCC death (adjusted hazard ratio = 1.48; 95% CI = 1.04-2.10). In conclusion, plasma MMP1 may serve as a noninvasive marker of detecting the presence and predicting the survival of ESCC.

AB - This study aimed to identify noninvasive protein markers capable of detecting the presence and prognosis of esophageal squamous-cell carcinoma (ESCC). Analyzing microarray expression data collected from 17-pair ESCC specimens, we identified one protein, matrix metalloproteinase-1 (MMP1), as a possibly useful marker. Plasma MMP1 was then measured by enzyme-linked immunosorbent assay (ELISA) in 210 ESCC patients and 197 healthy controls. ESCC patients had higher mean levels of MMP1 than controls (8.7 ± 7.5 vs. 6.7 ± 4.9 ng/mL, p < 0.0001). Using the highest quartile level (9.67 ng/mL) as cut-off, we found a 9.0-fold risk of ESCC in those with higher plasma MMP1 after adjusting for covariates (95% confidence interval = 2.2, 36.0). Heavy smokers and heavy drinkers with higher plasma MMP1 had 61.4-and 31.0 times the risk, respectively, than non-users with lower MMP1. In the survival analysis, compared to those with MMP1 ≤ 9.67 ng/mL, ESCC patients with MMP1 > 9.67 ng/mL had a 48% increase in the risk of ESCC death (adjusted hazard ratio = 1.48; 95% CI = 1.04-2.10). In conclusion, plasma MMP1 may serve as a noninvasive marker of detecting the presence and predicting the survival of ESCC.

UR - http://www.scopus.com/inward/record.url?scp=84979543909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979543909&partnerID=8YFLogxK

U2 - 10.1038/srep30057

DO - 10.1038/srep30057

M3 - Article

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 30057

ER -